103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB4352
 
Introduced , by Rep. Tom Weber
 
SYNOPSIS AS INTRODUCED:

720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/206 from Ch. 56 1/2, par. 1206
 Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances.


LRB103 35349 RLC 65413 b


 
 
A BILL FOR
 
HB4352LRB103 35349 RLC 65413 b


1 AN ACT concerning criminal law.

2 Be it enacted by the People of the State of Illinois, 
3represented in the General Assembly:

4 Section 5. The Illinois Controlled Substances Act is 
5amended by changing Sections 204 and 206 as follows:

6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
7 (Text of Section before amendment by P.A. 103-245)
8 Sec. 204. (a) The controlled substances listed in this 
9Section are included in Schedule I.
10 (b) Unless specifically excepted or unless listed in 
11another schedule, any of the following opiates, including 
12their isomers, esters, ethers, salts, and salts of isomers, 
13esters, and ethers, whenever the existence of such isomers, 
14esters, ethers and salts is possible within the specific 
15chemical designation:
16  (1) Acetylmethadol;
17  (1.1) Acetyl-alpha-methylfentanyl
18 (N-[1-(1-methyl-2-phenethyl)-

19 4-piperidinyl]-N-phenylacetamide);
20  (2) Allylprodine;
21  (3) Alphacetylmethadol, except

22 levo-alphacetylmethadol (also known as levo-alpha-

23 acetylmethadol, levomethadyl acetate, or LAAM);
 
 
HB4352- 2 -LRB103 35349 RLC 65413 b


1  (4) Alphameprodine;
2  (5) Alphamethadol;
3  (6) Alpha-methylfentanyl

4 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)

5 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-

6 propanilido) piperidine;
7  (6.1) Alpha-methylthiofentanyl

8 (N-[1-methyl-2-(2-thienyl)ethyl-

9 4-piperidinyl]-N-phenylpropanamide);
10  (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
11  (7.1) PEPAP

12 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
13  (8) Benzethidine;
14  (9) Betacetylmethadol;
15  (9.1) Beta-hydroxyfentanyl

16 (N-[1-(2-hydroxy-2-phenethyl)-

17 4-piperidinyl]-N-phenylpropanamide);
18  (10) Betameprodine;
19  (11) Betamethadol;
20  (12) Betaprodine;
21  (13) Clonitazene;
22  (14) Dextromoramide;
23  (15) Diampromide;
24  (16) Diethylthiambutene;
25  (17) Difenoxin;
26  (18) Dimenoxadol;
 
 
HB4352- 3 -LRB103 35349 RLC 65413 b


1  (19) Dimepheptanol;
2  (20) Dimethylthiambutene;
3  (21) Dioxaphetylbutyrate;
4  (22) Dipipanone;
5  (23) Ethylmethylthiambutene;
6  (24) Etonitazene;
7  (25) Etoxeridine;
8  (26) Furethidine;
9  (27) Hydroxpethidine;
10  (28) Ketobemidone;
11  (29) Levomoramide;
12  (30) Levophenacylmorphan;
13  (31) 3-Methylfentanyl

14 (N-[3-methyl-1-(2-phenylethyl)-

15 4-piperidyl]-N-phenylpropanamide);
16  (31.1) 3-Methylthiofentanyl

17 (N-[(3-methyl-1-(2-thienyl)ethyl-

18 4-piperidinyl]-N-phenylpropanamide);
19  (32) Morpheridine;
20  (33) Noracymethadol;
21  (34) Norlevorphanol;
22  (35) Normethadone;
23  (36) Norpipanone;
24  (36.1) Para-fluorofentanyl

25 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-

26 4-piperidinyl]propanamide);
 
 
HB4352- 4 -LRB103 35349 RLC 65413 b


1  (37) Phenadoxone;
2  (38) Phenampromide;
3  (39) Phenomorphan;
4  (40) Phenoperidine;
5  (41) Piritramide;
6  (42) Proheptazine;
7  (43) Properidine;
8  (44) Propiram;
9  (45) Racemoramide;
10  (45.1) Thiofentanyl

11 (N-phenyl-N-[1-(2-thienyl)ethyl-

12 4-piperidinyl]-propanamide);
13  (46) Tilidine;
14  (47) Trimeperidine;
15  (48) Beta-hydroxy-3-methylfentanyl (other name:

16 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-

17 N-phenylpropanamide);
18  (49) Furanyl fentanyl (FU-F);
19  (50) Butyryl fentanyl;
20  (51) Valeryl fentanyl;
21  (52) Acetyl fentanyl;
22  (53) Beta-hydroxy-thiofentanyl; 
23  (54) 3,4-dichloro-N-[2-

24 (dimethylamino)cyclohexyl]-N-

25 methylbenzamide (U-47700); 
26  (55) 4-chloro-N-[1-[2-

 
 
HB4352- 5 -LRB103 35349 RLC 65413 b


1 (4-nitrophenyl)ethyl]-2-piperidinylidene]-

2 benzenesulfonamide (W-18); 
3  (56) 4-chloro-N-[1-(2-phenylethyl)

4 -2-piperidinylidene]-benzenesulfonamide (W-15); 
5  (57) acrylfentanyl (acryloylfentanyl). 
6 (c) Unless specifically excepted or unless listed in 
7another schedule, any of the following opium derivatives, its 
8salts, isomers and salts of isomers, whenever the existence of 
9such salts, isomers and salts of isomers is possible within 
10the specific chemical designation:
11  (1) Acetorphine;
12  (2) Acetyldihydrocodeine;
13  (3) Benzylmorphine;
14  (4) Codeine methylbromide;
15  (5) Codeine-N-Oxide;
16  (6) Cyprenorphine;
17  (7) Desomorphine;
18  (8) Diacetyldihydromorphine (Dihydroheroin);
19  (9) Dihydromorphine;
20  (10) Drotebanol;
21  (11) Etorphine (except hydrochloride salt);
22  (12) Heroin;
23  (13) Hydromorphinol;
24  (14) Methyldesorphine;
25  (15) Methyldihydromorphine;
26  (16) Morphine methylbromide;
 
 
HB4352- 6 -LRB103 35349 RLC 65413 b


1  (17) Morphine methylsulfonate;
2  (18) Morphine-N-Oxide;
3  (19) Myrophine;
4  (20) Nicocodeine;
5  (21) Nicomorphine;
6  (22) Normorphine;
7  (23) Pholcodine;
8  (24) Thebacon.
9 (d) Unless specifically excepted or unless listed in 
10another schedule, any material, compound, mixture, or 
11preparation which contains any quantity of the following 
12hallucinogenic substances, or which contains any of its salts, 
13isomers and salts of isomers, whenever the existence of such 
14salts, isomers, and salts of isomers is possible within the 
15specific chemical designation (for the purposes of this 
16paragraph only, the term "isomer" includes the optical, 
17position and geometric isomers):
18  (1) 3,4-methylenedioxyamphetamine

19 (alpha-methyl,3,4-methylenedioxyphenethylamine,

20 methylenedioxyamphetamine, MDA);
21  (1.1) Alpha-ethyltryptamine

22 (some trade or other names: etryptamine;

23 MONASE; alpha-ethyl-1H-indole-3-ethanamine;

24 3-(2-aminobutyl)indole; a-ET; and AET);
25  (2) 3,4-methylenedioxymethamphetamine (MDMA);
26  (2.1) 3,4-methylenedioxy-N-ethylamphetamine

 
 
HB4352- 7 -LRB103 35349 RLC 65413 b


1 (also known as: N-ethyl-alpha-methyl-

2 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

3 and MDEA);
4  (2.2) N-Benzylpiperazine (BZP); 
5  (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); 
6  (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
7  (4) 3,4,5-trimethoxyamphetamine (TMA);
8  (5) (Blank);
9  (6) Diethyltryptamine (DET);
10  (7) Dimethyltryptamine (DMT);
11  (7.1) 5-Methoxy-diallyltryptamine; 
12  (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
13  (9) Ibogaine (some trade and other names:

14 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-

15 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

16 indole; Tabernanthe iboga);
17  (10) Lysergic acid diethylamide;
18  (10.1) Salvinorin A; 
19  (10.5) Salvia divinorum (meaning all parts of the 
20 plant presently classified botanically as Salvia 
21 divinorum, whether growing or not, the seeds thereof, any 
22 extract from any part of that plant, and every compound, 
23 manufacture, salts, isomers, and salts of isomers whenever 
24 the existence of such salts, isomers, and salts of isomers 
25 is possible within the specific chemical designation, 
26 derivative, mixture, or preparation of that plant, its 
 
 
HB4352- 8 -LRB103 35349 RLC 65413 b


1 seeds or extracts); 
2  (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
3  (12) Peyote (meaning all parts of the plant presently 
4 classified botanically as Lophophora williamsii Lemaire, 
5 whether growing or not, the seeds thereof, any extract 
6 from any part of that plant, and every compound, 
7 manufacture, salts, derivative, mixture, or preparation of 
8 that plant, its seeds or extracts);
9  (13) N-ethyl-3-piperidyl benzilate (JB 318);
10  (14) N-methyl-3-piperidyl benzilate;
11  (14.1) N-hydroxy-3,4-methylenedioxyamphetamine

12 (also known as N-hydroxy-alpha-methyl-

13 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
14  (15) Parahexyl; some trade or other names:

15 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-

16 dibenzo (b,d) pyran; Synhexyl;
17  (16) Psilocybin;
18  (17) Psilocyn;
19  (18) Alpha-methyltryptamine (AMT);
20  (19) 2,5-dimethoxyamphetamine

21 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
22  (20) 4-bromo-2,5-dimethoxyamphetamine

23 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

24 4-bromo-2,5-DMA);
25  (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

26 Some trade or other names: 2-(4-bromo-

 
 
HB4352- 9 -LRB103 35349 RLC 65413 b


1 2,5-dimethoxyphenyl)-1-aminoethane;

2 alpha-desmethyl DOB, 2CB, Nexus;
3  (21) 4-methoxyamphetamine

4 (4-methoxy-alpha-methylphenethylamine;

5 paramethoxyamphetamine; PMA);
6  (22) (Blank);
7  (23) Ethylamine analog of phencyclidine.

8 Some trade or other names:

9 N-ethyl-1-phenylcyclohexylamine,

10 (1-phenylcyclohexyl) ethylamine,

11 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
12  (24) Pyrrolidine analog of phencyclidine. Some trade 
13 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy, 
14 PHP;
15  (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
16  (26) 2,5-dimethoxy-4-ethylamphetamine

17 (another name: DOET);
18  (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

19 (another name: TCPy);
20  (28) (Blank);
21  (29) Thiophene analog of phencyclidine (some trade

22 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

23 2-thienyl analog of phencyclidine; TPCP; TCP);
24  (29.1) Benzothiophene analog of phencyclidine. Some 
25 trade or other names: BTCP or benocyclidine;
26  (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); 
 
 
HB4352- 10 -LRB103 35349 RLC 65413 b


1  (30) Bufotenine (some trade or other names:

2 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

3 3-(2-dimethylaminoethyl)-5-indolol;

4 5-hydroxy-N,N-dimethyltryptamine;

5 N,N-dimethylserotonin; mappine);
6  (31) (Blank); 
7  (32) (Blank); 
8  (33) (Blank); 
9  (34) (Blank); 
10  (34.5) (Blank); 
11  (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
12 (2-methyloctan-2-yl)-6a,7, 
13 10,10a-tetrahydrobenzo[c]chromen-1-ol
14 Some trade or other names: HU-210; 
15  (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- 
16 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
17 tetrahydrobenzo[c]chromen-1-ol, its isomers, 
18 salts, and salts of isomers; Some trade or other 
19 names: HU-210, Dexanabinol; 
20  (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
21 6,6-dimethyl-3-(2-methyloctan-2-yl)- 
22 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
23 Some trade or other names: HU-211;
24  (37) (Blank); 
25  (38) (Blank); 
26  (39) (Blank); 
 
 
HB4352- 11 -LRB103 35349 RLC 65413 b


1  (40) (Blank); 
2  (41) (Blank); 
3  (42) Any compound structurally derived from 
4 3-(1-naphthoyl)indole or 
5 1H-indol-3-yl-(1-naphthyl)methane by substitution at the 
6 nitrogen atom of the indole ring by alkyl, haloalkyl, 
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
9 2-(4-morpholinyl)ethyl whether or not further substituted 
10 in the indole ring to any extent, whether or not 
11 substituted in the naphthyl ring to any extent. Examples 
12 of this structural class include, but are not limited to, 
13 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
14  (43) Any compound structurally derived from 
15 3-(1-naphthoyl)pyrrole by substitution at the nitrogen 
16 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, 
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
19 2-(4-morpholinyl)ethyl, whether or not further substituted 
20 in the pyrrole ring to any extent, whether or not 
21 substituted in the naphthyl ring to any extent. Examples 
22 of this structural class include, but are not limited to, 
23 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; 
24  (44) Any compound structurally derived from 
25 1-(1-naphthylmethyl)indene by substitution at the 
26 3-position of the indene ring by alkyl, haloalkyl, 
 
 
HB4352- 12 -LRB103 35349 RLC 65413 b


1 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
2 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
3 2-(4-morpholinyl)ethyl whether or not further substituted 
4 in the indene ring to any extent, whether or not 
5 substituted in the naphthyl ring to any extent. Examples 
6 of this structural class include, but are not limited to, 
7 JWH-176; 
8  (45) Any compound structurally derived from 
9 3-phenylacetylindole by substitution at the nitrogen atom 
10 of the indole ring with alkyl, haloalkyl, alkenyl, 
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
12 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
13 2-(4-morpholinyl)ethyl, whether or not further substituted 
14 in the indole ring to any extent, whether or not 
15 substituted in the phenyl ring to any extent. Examples of 
16 this structural class include, but are not limited to, 
17 JWH-167, JWH-250, JWH-251, and RCS-8; 
18  (46) Any compound structurally derived from 
19 2-(3-hydroxycyclohexyl)phenol by substitution at the 
20 5-position of the phenolic ring by alkyl, haloalkyl, 
21 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
22 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
23 2-(4-morpholinyl)ethyl, whether or not substituted in the 
24 cyclohexyl ring to any extent. Examples of this structural 
25 class include, but are not limited to, CP 47, 497 and its 
26 C8 homologue (cannabicyclohexanol); 
 
 
HB4352- 13 -LRB103 35349 RLC 65413 b


1  (46.1) Any compound structurally derived from 
2 3-(benzoyl) indole with substitution at the nitrogen atom 
3 of the indole ring by an alkyl, haloalkyl, alkenyl, 
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
5 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
6 2-(4-morpholinyl)ethyl group whether or not further 
7 substituted in the indole ring to any extent and whether 
8 or not substituted in the phenyl ring to any extent. 
9 Examples of this structural class include, but are not 
10 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN 
11 48,098), and RCS-4; 
12  (47) (Blank); 
13  (48) (Blank); 
14  (49) (Blank); 
15  (50) (Blank); 
16  (51) (Blank); 
17  (52) (Blank); 
18  (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. 
19 Some trade or other names: 2C-T-7; 
20  (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some 
21 trade or other names: 2C-E; 
22  (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some 
23 trade or other names: 2C-D; 
24  (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some 
25 trade or other names: 2C-C; 
26  (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade 
 
 
HB4352- 14 -LRB103 35349 RLC 65413 b


1 or other names: 2C-I; 
2  (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some 
3 trade or other names: 2C-T-2; 
4  (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. 
5 Some trade or other names: 2C-T-4; 
6  (53.7) 2,5-dimethoxyphenethylamine. Some trade or 
7 other names: 2C-H; 
8  (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some 
9 trade or other names: 2C-N; 
10  (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some 
11 trade or other names: 2C-P; 
12  (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. 
13 Some trade or other names: 2C-G; 
14  (53.11) The N-(2-methoxybenzyl) derivative of any 2C 
15 phenethylamine referred to in subparagraphs (20.1), (53), 
16 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), 
17 (53.8), (53.9), and (53.10) including, but not limited to, 
18 25I-NBOMe and 25C-NBOMe; 
19  (54) 5-Methoxy-N,N-diisopropyltryptamine; 
20  (55) (Blank); 
21  (56) (Blank); 
22  (57) (Blank); 
23  (58) (Blank); 
24  (59) 3-cyclopropoylindole with substitution at the 
25 nitrogen atom of the indole ring by alkyl, haloalkyl, 
26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
 
 
HB4352- 15 -LRB103 35349 RLC 65413 b


1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
2 2-(4-morpholinyl)ethyl, whether or not further substituted 
3 on the indole ring to any extent, whether or not 
4 substituted on the cyclopropyl ring to any extent: 
5 including, but not limited to, XLR11, UR144, FUB-144; 
6  (60) 3-adamantoylindole with substitution at the 
7 nitrogen atom of the indole ring by alkyl, haloalkyl, 
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
9 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
10 2-(4-morpholinyl)ethyl, whether or not further substituted 
11 on the indole ring to any extent, whether or not 
12 substituted on the adamantyl ring to any extent: 
13 including, but not limited to, AB-001; 
14  (61) N-(adamantyl)-indole-3-carboxamide with 
15 substitution at the nitrogen atom of the indole ring by 
16 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
17 cycloalkylethyl, aryl halide, alkyl aryl halide, 
18 1-(N-methyl-2-piperidinyl)methyl, or 
19 2-(4-morpholinyl)ethyl, whether or not further substituted 
20 on the indole ring to any extent, whether or not 
21 substituted on the adamantyl ring to any extent: 
22 including, but not limited to, APICA/2NE-1, STS-135; 
23  (62) N-(adamantyl)-indazole-3-carboxamide with 
24 substitution at a nitrogen atom of the indazole ring by 
25 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
26 cycloalkylethyl, aryl halide, alkyl aryl halide, 
 
 
HB4352- 16 -LRB103 35349 RLC 65413 b


1 1-(N-methyl-2-piperidinyl)methyl, or 
2 2-(4-morpholinyl)ethyl, whether or not further substituted 
3 on the indazole ring to any extent, whether or not 
4 substituted on the adamantyl ring to any extent: 
5 including, but not limited to, AKB48, 5F-AKB48; 
6  (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester 
7 with substitution at the nitrogen atom of the indole ring 
8 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
9 cycloalkylethyl, aryl halide, alkyl aryl halide, 
10 1-(N-methyl-2-piperidinyl)methyl, or 
11 2-(4-morpholinyl)ethyl, whether or not further substituted 
12 on the indole ring to any extent, whether or not 
13 substituted on the quinoline ring to any extent: 
14 including, but not limited to, PB22, 5F-PB22, FUB-PB-22; 
15  (64) 3-(1-naphthoyl)indazole with substitution at the 
16 nitrogen atom of the indazole ring by alkyl, haloalkyl, 
17 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
18 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
19 2-(4-morpholinyl)ethyl, whether or not further substituted 
20 on the indazole ring to any extent, whether or not 
21 substituted on the naphthyl ring to any extent: including, 
22 but not limited to, THJ-018, THJ-2201; 
23  (65) 2-(1-naphthoyl)benzimidazole with substitution 
24 at the nitrogen atom of the benzimidazole ring by alkyl, 
25 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
26 aryl halide, alkyl aryl halide, 
 
 
HB4352- 17 -LRB103 35349 RLC 65413 b


1 1-(N-methyl-2-piperidinyl)methyl, or 
2 2-(4-morpholinyl)ethyl, whether or not further substituted 
3 on the benzimidazole ring to any extent, whether or not 
4 substituted on the naphthyl ring to any extent: including, 
5 but not limited to, FUBIMINA; 
6  (66) 
7 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- 
8 3-carboxamide with substitution on the nitrogen atom of 
9 the indazole ring by alkyl, haloalkyl, alkenyl, 
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
11 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
12 2-(4-morpholinyl)ethyl, whether or not further substituted 
13 on the indazole ring to any extent: including, but not 
14 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; 
15  (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- 
16 indazole-3-carboxamide with substitution on the nitrogen 
17 atom of the indazole ring by alkyl, haloalkyl, alkenyl, 
18 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
19 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
20 2-(4-morpholinyl)ethyl, whether or not further substituted 
21 on the indazole ring to any extent: including, but not 
22 limited to, ADB-PINACA, ADB-FUBINACA; 
23  (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- 
24 indole-3-carboxamide with substitution on the nitrogen 
25 atom of the indole ring by alkyl, haloalkyl, alkenyl, 
26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
 
 
HB4352- 18 -LRB103 35349 RLC 65413 b


1 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
2 2-(4-morpholinyl)ethyl, whether or not further substituted 
3 on the indole ring to any extent: including, but not 
4 limited to, ADBICA, 5F-ADBICA; 
5  (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- 
6 3-carboxamide with substitution on the nitrogen atom of 
7 the indole ring by alkyl, haloalkyl, alkenyl, 
8 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
9 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
10 2-(4-morpholinyl)ethyl, whether or not further substituted 
11 on the indole ring to any extent: including, but not 
12 limited to, ABICA, 5F-ABICA; 
13  (70) Methyl 2-(1H-indazole-3-carboxamido)-3- 
14 methylbutanoate with substitution on the nitrogen atom of 
15 the indazole ring by alkyl, haloalkyl, alkenyl, 
16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
17 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
18 2-(4-morpholinyl)ethyl, whether or not further substituted 
19 on the indazole ring to any extent: including, but not 
20 limited to, AMB, 5F-AMB; 
21  (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- 
22 dimethylbutanoate with substitution on the nitrogen atom 
23 of the indazole ring by alkyl, haloalkyl, alkenyl, 
24 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
25 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
26 2-(4-morpholinyl)ethyl, whether or not further substituted 
 
 
HB4352- 19 -LRB103 35349 RLC 65413 b


1 on the indazole ring to any extent: including, but not 
2 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; 
3  (72) Methyl 2-(1H-indole-3-carboxamido)-3- 
4 methylbutanoate with substitution on the nitrogen atom of 
5 the indole ring by alkyl, haloalkyl, alkenyl, 
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
7 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
8 2-(4-morpholinyl)ethyl, whether or not further substituted 
9 on the indazole ring to any extent: including, but not 
10 limited to, MMB018, MMB2201, and AMB-CHMICA; 
11  (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- 
12 dimethylbutanoate with substitution on the nitrogen atom 
13 of the indole ring by alkyl, haloalkyl, alkenyl, 
14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
15 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
16 2-(4-morpholinyl)ethyl, whether or not further substituted 
17 on the indazole ring to any extent: including, but not 
18 limited to, MDMB-CHMICA; 
19  (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- 
20 indazole-3-carboxamide with substitution on the nitrogen 
21 atom of the indazole ring by alkyl, haloalkyl, alkenyl, 
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
24 2-(4-morpholinyl)ethyl, whether or not further substituted 
25 on the indazole ring to any  extent: including, but not 
26 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA; 
 
 
HB4352- 20 -LRB103 35349 RLC 65413 b


1  (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- 
2 3-carboxamide with substitution on the nitrogen atom of 
3 the indole ring by alkyl, haloalkyl, alkenyl, 
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
5 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
6 2-(4-morpholinyl)ethyl, whether or not further substituted 
7 on the indazole ring to any extent: including, but not 
8 limited to, APP-PICA and 5-fluoro-APP-PICA; 
9  (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name 
10 4-AcO-DMT;
11  (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade 
12 name 5-MeO-MIPT;
13  (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
14  (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
15  (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
16  (81) 4-hydroxy-N-methyl-N-isopropyltryptamine 
17 (4-HO-MiPT); 
18  (82) Fluorophenylpiperazine;
19  (83) Methoxetamine;
20  (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- 
21 ethcathinone). 
22 (e) Unless specifically excepted or unless listed in 
23another schedule, any material, compound, mixture, or 
24preparation which contains any quantity of the following 
25substances having a depressant effect on the central nervous 
26system, including its salts, isomers, and salts of isomers 
 
 
HB4352- 21 -LRB103 35349 RLC 65413 b


1whenever the existence of such salts, isomers, and salts of 
2isomers is possible within the specific chemical designation:
3  (1) mecloqualone;
4  (2) methaqualone; and
5  (3) gamma hydroxybutyric acid.
6 (f) Unless specifically excepted or unless listed in 
7another schedule, any material, compound, mixture, or 
8preparation which contains any quantity of the following 
9substances having a stimulant effect on the central nervous 
10system, including its salts, isomers, and salts of isomers:
11  (1) Fenethylline;
12  (2) N-ethylamphetamine;
13  (3) Aminorex (some other names:

14 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

15 4-5-dihydro-5-phenyl-2-oxazolamine) and its

16 salts, optical isomers, and salts of optical isomers;
17  (4) Methcathinone (some other names:

18 2-methylamino-1-phenylpropan-1-one;

19 Ephedrone; 2-(methylamino)-propiophenone;

20 alpha-(methylamino)propiophenone; N-methylcathinone;

21 methycathinone; Monomethylpropion; UR 1431) and its

22 salts, optical isomers, and salts of optical isomers;
23  (5) Cathinone (some trade or other names:

24 2-aminopropiophenone; alpha-aminopropiophenone;

25 2-amino-1-phenyl-propanone; norephedrone);
26  (6) N,N-dimethylamphetamine (also known as:

 
 
HB4352- 22 -LRB103 35349 RLC 65413 b


1 N,N-alpha-trimethyl-benzeneethanamine;

2 N,N-alpha-trimethylphenethylamine);
3  (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

4 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
5  (8) 3,4-Methylenedioxypyrovalerone (MDPV); 
6  (9) Halogenated amphetamines and

7 methamphetamines - any compound derived from either

8 amphetamine or methamphetamine through the substitution

9 of a halogen on the phenyl ring, including, but not

10 limited to, 2-fluoroamphetamine, 3-

11 fluoroamphetamine and 4-fluoroamphetamine; 
12  (10) Aminopropylbenzofuran (APB):

13 including 4-(2-Aminopropyl) benzofuran, 5-

14 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)

15 benzofuran, and 7-(2-Aminopropyl) benzofuran; 
16  (11) Aminopropyldihydrobenzofuran (APDB):

17 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,

18 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,

19 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,

20 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
21  (12) Methylaminopropylbenzofuran

22 (MAPB): including 4-(2-methylaminopropyl)

23 benzofuran, 5-(2-methylaminopropyl)benzofuran,

24 6-(2-methylaminopropyl)benzofuran

25 and 7-(2-methylaminopropyl)benzofuran. 
26 (g) Temporary listing of substances subject to emergency 
 
 
HB4352- 23 -LRB103 35349 RLC 65413 b


1scheduling. Any material, compound, mixture, or preparation 
2that contains any quantity of the following substances:
3  (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide 
4 (benzylfentanyl), its optical isomers, isomers, salts, and 
5 salts of isomers;
6  (2) N-[1(2-thienyl) methyl-4-piperidyl]-N- 
7 phenylpropanamide (thenylfentanyl), its optical isomers, 
8 salts, and salts of isomers.
9 (h) Synthetic cathinones. Unless specifically excepted, 
10any chemical compound which is not approved by the United 
11States Food and Drug Administration or, if approved, is not 
12dispensed or possessed in accordance with State or federal 
13law, not including bupropion, structurally derived from 
142-aminopropan-1-one by substitution at the 1-position with 
15either phenyl, naphthyl, or thiophene ring systems, whether or 
16not the compound is further modified in one or more of the 
17following ways: 
18  (1) by substitution in the ring system to any extent 
19 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or 
20 halide substituents, whether or not further substituted in 
21 the ring system by one or more other univalent 
22 substituents. Examples of this class include, but are not 
23 limited to, 3,4-Methylenedioxycathinone (bk-MDA); 
24  (2) by substitution at the 3-position with an acyclic 
25 alkyl substituent. Examples of this class include, but are 
26 not limited to, 2-methylamino-1-phenylbutan-1-one 
 
 
HB4352- 24 -LRB103 35349 RLC 65413 b


1 (buphedrone); or 
2  (3) by substitution at the 2-amino nitrogen atom with 
3 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by 
4 inclusion of the 2-amino nitrogen atom in a cyclic 
5 structure. Examples of this class include, but are not 
6 limited to, Dimethylcathinone, Ethcathinone, and 
7 a-Pyrrolidinopropiophenone (a-PPP); or 
8 Any other synthetic cathinone which is not approved by the 
9United States Food and Drug Administration or, if approved, is 
10not dispensed or possessed in accordance with State or federal 
11law. 
12 (i) Synthetic cannabinoids or piperazines. Any synthetic 
13cannabinoid or piperazine which is not approved by the United 
14States Food and Drug Administration or, if approved, which is 
15not dispensed or possessed in accordance with State and 
16federal law.
17(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; 
18100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. 
198-14-18.)

20 (Text of Section after amendment by P.A. 103-245)
21 Sec. 204. (a) The controlled substances listed in this 
22Section are included in Schedule I.
23 (b) Unless specifically excepted or unless listed in 
24another schedule, any of the following opiates, including 
25their isomers, esters, ethers, salts, and salts of isomers, 
 
 
HB4352- 25 -LRB103 35349 RLC 65413 b


1esters, and ethers, whenever the existence of such isomers, 
2esters, ethers and salts is possible within the specific 
3chemical designation:
4  (1) Acetylmethadol;
5  (1.1) Acetyl-alpha-methylfentanyl
6 (N-[1-(1-methyl-2-phenethyl)-

7 4-piperidinyl]-N-phenylacetamide);
8  (2) Allylprodine;
9  (3) Alphacetylmethadol, except

10 levo-alphacetylmethadol (also known as levo-alpha-

11 acetylmethadol, levomethadyl acetate, or LAAM);
12  (4) Alphameprodine;
13  (5) Alphamethadol;
14  (6) Alpha-methylfentanyl

15 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)

16 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-

17 propanilido) piperidine;
18  (6.1) Alpha-methylthiofentanyl

19 (N-[1-methyl-2-(2-thienyl)ethyl-

20 4-piperidinyl]-N-phenylpropanamide);
21  (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
22  (7.1) PEPAP

23 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
24  (8) Benzethidine;
25  (9) Betacetylmethadol;
26  (9.1) Beta-hydroxyfentanyl

 
 
HB4352- 26 -LRB103 35349 RLC 65413 b


1 (N-[1-(2-hydroxy-2-phenethyl)-

2 4-piperidinyl]-N-phenylpropanamide);
3  (10) Betameprodine;
4  (11) Betamethadol;
5  (12) Betaprodine;
6  (13) Clonitazene;
7  (14) Dextromoramide;
8  (15) Diampromide;
9  (16) Diethylthiambutene;
10  (17) Difenoxin;
11  (18) Dimenoxadol;
12  (19) Dimepheptanol;
13  (20) Dimethylthiambutene;
14  (21) Dioxaphetylbutyrate;
15  (22) Dipipanone;
16  (23) Ethylmethylthiambutene;
17  (24) Etonitazene;
18  (25) Etoxeridine;
19  (26) Furethidine;
20  (27) Hydroxpethidine;
21  (28) Ketobemidone;
22  (29) Levomoramide;
23  (30) Levophenacylmorphan;
24  (31) 3-Methylfentanyl

25 (N-[3-methyl-1-(2-phenylethyl)-

26 4-piperidyl]-N-phenylpropanamide);
 
 
HB4352- 27 -LRB103 35349 RLC 65413 b


1  (31.1) 3-Methylthiofentanyl

2 (N-[(3-methyl-1-(2-thienyl)ethyl-

3 4-piperidinyl]-N-phenylpropanamide);
4  (32) Morpheridine;
5  (33) Noracymethadol;
6  (34) Norlevorphanol;
7  (35) Normethadone;
8  (36) Norpipanone;
9  (36.1) Para-fluorofentanyl

10 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-

11 4-piperidinyl]propanamide);
12  (37) Phenadoxone;
13  (38) Phenampromide;
14  (39) Phenomorphan;
15  (40) Phenoperidine;
16  (41) Piritramide;
17  (42) Proheptazine;
18  (43) Properidine;
19  (44) Propiram;
20  (45) Racemoramide;
21  (45.1) Thiofentanyl

22 (N-phenyl-N-[1-(2-thienyl)ethyl-

23 4-piperidinyl]-propanamide);
24  (46) Tilidine;
25  (47) Trimeperidine;
26  (48) Beta-hydroxy-3-methylfentanyl (other name:

 
 
HB4352- 28 -LRB103 35349 RLC 65413 b


1 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-

2 N-phenylpropanamide);
3  (49) Furanyl fentanyl (FU-F);
4  (50) Butyryl fentanyl;
5  (51) Valeryl fentanyl;
6  (52) Acetyl fentanyl;
7  (53) Beta-hydroxy-thiofentanyl; 
8  (54) 3,4-dichloro-N-[2-

9 (dimethylamino)cyclohexyl]-N-

10 methylbenzamide (U-47700); 
11  (55) 4-chloro-N-[1-[2-

12 (4-nitrophenyl)ethyl]-2-piperidinylidene]-

13 benzenesulfonamide (W-18); 
14  (56) 4-chloro-N-[1-(2-phenylethyl)

15 -2-piperidinylidene]-benzenesulfonamide (W-15); 
16  (57) acrylfentanyl (acryloylfentanyl). 
17 (c) Unless specifically excepted or unless listed in 
18another schedule, any of the following opium derivatives, its 
19salts, isomers and salts of isomers, whenever the existence of 
20such salts, isomers and salts of isomers is possible within 
21the specific chemical designation:
22  (1) Acetorphine;
23  (2) Acetyldihydrocodeine;
24  (3) Benzylmorphine;
25  (4) Codeine methylbromide;
26  (5) Codeine-N-Oxide;
 
 
HB4352- 29 -LRB103 35349 RLC 65413 b


1  (6) Cyprenorphine;
2  (7) Desomorphine;
3  (8) Diacetyldihydromorphine (Dihydroheroin);
4  (9) Dihydromorphine;
5  (10) Drotebanol;
6  (11) Etorphine (except hydrochloride salt);
7  (12) Heroin;
8  (13) Hydromorphinol;
9  (14) Methyldesorphine;
10  (15) Methyldihydromorphine;
11  (16) Morphine methylbromide;
12  (17) Morphine methylsulfonate;
13  (18) Morphine-N-Oxide;
14  (19) Myrophine;
15  (20) Nicocodeine;
16  (21) Nicomorphine;
17  (22) Normorphine;
18  (23) Pholcodine;
19  (24) Thebacon.
20 (d) Unless specifically excepted or unless listed in 
21another schedule, any material, compound, mixture, or 
22preparation which contains any quantity of the following 
23hallucinogenic substances, or which contains any of its salts, 
24isomers and salts of isomers, whenever the existence of such 
25salts, isomers, and salts of isomers is possible within the 
26specific chemical designation (for the purposes of this 
 
 
HB4352- 30 -LRB103 35349 RLC 65413 b


1paragraph only, the term "isomer" includes the optical, 
2position and geometric isomers):
3  (1) 3,4-methylenedioxyamphetamine

4 (alpha-methyl,3,4-methylenedioxyphenethylamine,

5 methylenedioxyamphetamine, MDA);
6  (1.1) Alpha-ethyltryptamine

7 (some trade or other names: etryptamine;

8 MONASE; alpha-ethyl-1H-indole-3-ethanamine;

9 3-(2-aminobutyl)indole; a-ET; and AET);
10  (2) 3,4-methylenedioxymethamphetamine (MDMA);
11  (2.1) 3,4-methylenedioxy-N-ethylamphetamine

12 (also known as: N-ethyl-alpha-methyl-

13 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

14 and MDEA);
15  (2.2) N-Benzylpiperazine (BZP); 
16  (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); 
17  (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
18  (4) 3,4,5-trimethoxyamphetamine (TMA);
19  (5) (Blank);
20  (6) Diethyltryptamine (DET);
21  (7) Dimethyltryptamine (DMT);
22  (7.1) 5-Methoxy-diallyltryptamine; 
23  (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
24  (9) Ibogaine (some trade and other names:

25 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-

26 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

 
 
HB4352- 31 -LRB103 35349 RLC 65413 b


1 indole; Tabernanthe iboga);
2  (10) Lysergic acid diethylamide;
3  (10.1) Salvinorin A; 
4  (10.5) Salvia divinorum (meaning all parts of the 
5 plant presently classified botanically as Salvia 
6 divinorum, whether growing or not, the seeds thereof, any 
7 extract from any part of that plant, and every compound, 
8 manufacture, salts, isomers, and salts of isomers whenever 
9 the existence of such salts, isomers, and salts of isomers 
10 is possible within the specific chemical designation, 
11 derivative, mixture, or preparation of that plant, its 
12 seeds or extracts); 
13  (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
14  (12) Peyote (meaning all parts of the plant presently 
15 classified botanically as Lophophora williamsii Lemaire, 
16 whether growing or not, the seeds thereof, any extract 
17 from any part of that plant, and every compound, 
18 manufacture, salts, derivative, mixture, or preparation of 
19 that plant, its seeds or extracts);
20  (13) N-ethyl-3-piperidyl benzilate (JB 318);
21  (14) N-methyl-3-piperidyl benzilate;
22  (14.1) N-hydroxy-3,4-methylenedioxyamphetamine

23 (also known as N-hydroxy-alpha-methyl-

24 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
25  (15) Parahexyl; some trade or other names:

26 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-

 
 
HB4352- 32 -LRB103 35349 RLC 65413 b


1 dibenzo (b,d) pyran; Synhexyl;
2  (16) Psilocybin;
3  (17) Psilocyn;
4  (18) Alpha-methyltryptamine (AMT);
5  (19) 2,5-dimethoxyamphetamine

6 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
7  (20) 4-bromo-2,5-dimethoxyamphetamine

8 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

9 4-bromo-2,5-DMA);
10  (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

11 Some trade or other names: 2-(4-bromo-

12 2,5-dimethoxyphenyl)-1-aminoethane;

13 alpha-desmethyl DOB, 2CB, Nexus;
14  (21) 4-methoxyamphetamine

15 (4-methoxy-alpha-methylphenethylamine;

16 paramethoxyamphetamine; PMA);
17  (22) (Blank);
18  (23) Ethylamine analog of phencyclidine.

19 Some trade or other names:

20 N-ethyl-1-phenylcyclohexylamine,

21 (1-phenylcyclohexyl) ethylamine,

22 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
23  (24) Pyrrolidine analog of phencyclidine. Some trade 
24 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy, 
25 PHP;
26  (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
 
 
HB4352- 33 -LRB103 35349 RLC 65413 b


1  (26) 2,5-dimethoxy-4-ethylamphetamine

2 (another name: DOET);
3  (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

4 (another name: TCPy);
5  (28) (Blank);
6  (29) Thiophene analog of phencyclidine (some trade

7 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

8 2-thienyl analog of phencyclidine; TPCP; TCP);
9  (29.1) Benzothiophene analog of phencyclidine. Some 
10 trade or other names: BTCP or benocyclidine;
11  (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); 
12  (30) Bufotenine (some trade or other names:

13 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

14 3-(2-dimethylaminoethyl)-5-indolol;

15 5-hydroxy-N,N-dimethyltryptamine;

16 N,N-dimethylserotonin; mappine);
17  (31) (Blank); 
18  (32) (Blank); 
19  (33) (Blank); 
20  (34) (Blank); 
21  (34.5) (Blank); 
22  (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
23 (2-methyloctan-2-yl)-6a,7, 
24 10,10a-tetrahydrobenzo[c]chromen-1-ol
25 Some trade or other names: HU-210; 
26  (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- 
 
 
HB4352- 34 -LRB103 35349 RLC 65413 b


1 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
2 tetrahydrobenzo[c]chromen-1-ol, its isomers, 
3 salts, and salts of isomers; Some trade or other 
4 names: HU-210, Dexanabinol; 
5  (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
6 6,6-dimethyl-3-(2-methyloctan-2-yl)- 
7 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
8 Some trade or other names: HU-211;
9  (37) (Blank); 
10  (38) (Blank); 
11  (39) (Blank); 
12  (40) (Blank); 
13  (41) (Blank); 
14  (42) Any compound structurally derived from 
15 3-(1-naphthoyl)indole or 
16 1H-indol-3-yl-(1-naphthyl)methane by substitution at the 
17 nitrogen atom of the indole ring by alkyl, haloalkyl, 
18 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
19 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
20 2-(4-morpholinyl)ethyl whether or not further substituted 
21 in the indole ring to any extent, whether or not 
22 substituted in the naphthyl ring to any extent. Examples 
23 of this structural class include, but are not limited to, 
24 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
25  (43) Any compound structurally derived from 
26 3-(1-naphthoyl)pyrrole by substitution at the nitrogen 
 
 
HB4352- 35 -LRB103 35349 RLC 65413 b


1 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, 
2 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
3 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
4 2-(4-morpholinyl)ethyl, whether or not further substituted 
5 in the pyrrole ring to any extent, whether or not 
6 substituted in the naphthyl ring to any extent. Examples 
7 of this structural class include, but are not limited to, 
8 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; 
9  (44) Any compound structurally derived from 
10 1-(1-naphthylmethyl)indene by substitution at the 
11 3-position of the indene ring by alkyl, haloalkyl, 
12 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
13 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
14 2-(4-morpholinyl)ethyl whether or not further substituted 
15 in the indene ring to any extent, whether or not 
16 substituted in the naphthyl ring to any extent. Examples 
17 of this structural class include, but are not limited to, 
18 JWH-176; 
19  (45) Any compound structurally derived from 
20 3-phenylacetylindole by substitution at the nitrogen atom 
21 of the indole ring with alkyl, haloalkyl, alkenyl, 
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
24 2-(4-morpholinyl)ethyl, whether or not further substituted 
25 in the indole ring to any extent, whether or not 
26 substituted in the phenyl ring to any extent. Examples of 
 
 
HB4352- 36 -LRB103 35349 RLC 65413 b


1 this structural class include, but are not limited to, 
2 JWH-167, JWH-250, JWH-251, and RCS-8; 
3  (46) Any compound structurally derived from 
4 2-(3-hydroxycyclohexyl)phenol by substitution at the 
5 5-position of the phenolic ring by alkyl, haloalkyl, 
6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
8 2-(4-morpholinyl)ethyl, whether or not substituted in the 
9 cyclohexyl ring to any extent. Examples of this structural 
10 class include, but are not limited to, CP 47, 497 and its 
11 C8 homologue (cannabicyclohexanol); 
12  (46.1) Any compound structurally derived from 
13 3-(benzoyl) indole with substitution at the nitrogen atom 
14 of the indole ring by an alkyl, haloalkyl, alkenyl, 
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
17 2-(4-morpholinyl)ethyl group whether or not further 
18 substituted in the indole ring to any extent and whether 
19 or not substituted in the phenyl ring to any extent. 
20 Examples of this structural class include, but are not 
21 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN 
22 48,098), and RCS-4; 
23  (47) (Blank); 
24  (48) (Blank); 
25  (49) (Blank); 
26  (50) (Blank); 
 
 
HB4352- 37 -LRB103 35349 RLC 65413 b


1  (51) (Blank); 
2  (52) (Blank); 
3  (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. 
4 Some trade or other names: 2C-T-7; 
5  (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some 
6 trade or other names: 2C-E; 
7  (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some 
8 trade or other names: 2C-D; 
9  (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some 
10 trade or other names: 2C-C; 
11  (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade 
12 or other names: 2C-I; 
13  (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some 
14 trade or other names: 2C-T-2; 
15  (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. 
16 Some trade or other names: 2C-T-4; 
17  (53.7) 2,5-dimethoxyphenethylamine. Some trade or 
18 other names: 2C-H; 
19  (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some 
20 trade or other names: 2C-N; 
21  (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some 
22 trade or other names: 2C-P; 
23  (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. 
24 Some trade or other names: 2C-G; 
25  (53.11) The N-(2-methoxybenzyl) derivative of any 2C 
26 phenethylamine referred to in subparagraphs (20.1), (53), 
 
 
HB4352- 38 -LRB103 35349 RLC 65413 b


1 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), 
2 (53.8), (53.9), and (53.10) including, but not limited to, 
3 25I-NBOMe and 25C-NBOMe; 
4  (54) 5-Methoxy-N,N-diisopropyltryptamine; 
5  (55) (Blank); 
6  (56) (Blank); 
7  (57) (Blank); 
8  (58) (Blank); 
9  (59) 3-cyclopropoylindole with substitution at the 
10 nitrogen atom of the indole ring by alkyl, haloalkyl, 
11 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
12 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
13 2-(4-morpholinyl)ethyl, whether or not further substituted 
14 on the indole ring to any extent, whether or not 
15 substituted on the cyclopropyl ring to any extent: 
16 including, but not limited to, XLR11, UR144, FUB-144; 
17  (60) 3-adamantoylindole with substitution at the 
18 nitrogen atom of the indole ring by alkyl, haloalkyl, 
19 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
20 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
21 2-(4-morpholinyl)ethyl, whether or not further substituted 
22 on the indole ring to any extent, whether or not 
23 substituted on the adamantyl ring to any extent: 
24 including, but not limited to, AB-001; 
25  (61) N-(adamantyl)-indole-3-carboxamide with 
26 substitution at the nitrogen atom of the indole ring by 
 
 
HB4352- 39 -LRB103 35349 RLC 65413 b


1 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
2 cycloalkylethyl, aryl halide, alkyl aryl halide, 
3 1-(N-methyl-2-piperidinyl)methyl, or 
4 2-(4-morpholinyl)ethyl, whether or not further substituted 
5 on the indole ring to any extent, whether or not 
6 substituted on the adamantyl ring to any extent: 
7 including, but not limited to, APICA/2NE-1, STS-135; 
8  (62) N-(adamantyl)-indazole-3-carboxamide with 
9 substitution at a nitrogen atom of the indazole ring by 
10 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
11 cycloalkylethyl, aryl halide, alkyl aryl halide, 
12 1-(N-methyl-2-piperidinyl)methyl, or 
13 2-(4-morpholinyl)ethyl, whether or not further substituted 
14 on the indazole ring to any extent, whether or not 
15 substituted on the adamantyl ring to any extent: 
16 including, but not limited to, AKB48, 5F-AKB48; 
17  (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester 
18 with substitution at the nitrogen atom of the indole ring 
19 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
20 cycloalkylethyl, aryl halide, alkyl aryl halide, 
21 1-(N-methyl-2-piperidinyl)methyl, or 
22 2-(4-morpholinyl)ethyl, whether or not further substituted 
23 on the indole ring to any extent, whether or not 
24 substituted on the quinoline ring to any extent: 
25 including, but not limited to, PB22, 5F-PB22, FUB-PB-22; 
26  (64) 3-(1-naphthoyl)indazole with substitution at the 
 
 
HB4352- 40 -LRB103 35349 RLC 65413 b


1 nitrogen atom of the indazole ring by alkyl, haloalkyl, 
2 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, 
3 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
4 2-(4-morpholinyl)ethyl, whether or not further substituted 
5 on the indazole ring to any extent, whether or not 
6 substituted on the naphthyl ring to any extent: including, 
7 but not limited to, THJ-018, THJ-2201; 
8  (65) 2-(1-naphthoyl)benzimidazole with substitution 
9 at the nitrogen atom of the benzimidazole ring by alkyl, 
10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
11 aryl halide, alkyl aryl halide, 
12 1-(N-methyl-2-piperidinyl)methyl, or 
13 2-(4-morpholinyl)ethyl, whether or not further substituted 
14 on the benzimidazole ring to any extent, whether or not 
15 substituted on the naphthyl ring to any extent: including, 
16 but not limited to, FUBIMINA; 
17  (66) 
18 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- 
19 3-carboxamide with substitution on the nitrogen atom of 
20 the indazole ring by alkyl, haloalkyl, alkenyl, 
21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
22 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
23 2-(4-morpholinyl)ethyl, whether or not further substituted 
24 on the indazole ring to any extent: including, but not 
25 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; 
26  (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- 
 
 
HB4352- 41 -LRB103 35349 RLC 65413 b


1 indazole-3-carboxamide with substitution on the nitrogen 
2 atom of the indazole ring by alkyl, haloalkyl, alkenyl, 
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
5 2-(4-morpholinyl)ethyl, whether or not further substituted 
6 on the indazole ring to any extent: including, but not 
7 limited to, ADB-PINACA, ADB-FUBINACA; 
8  (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- 
9 indole-3-carboxamide with substitution on the nitrogen 
10 atom of the indole ring by alkyl, haloalkyl, alkenyl, 
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
12 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
13 2-(4-morpholinyl)ethyl, whether or not further substituted 
14 on the indole ring to any extent: including, but not 
15 limited to, ADBICA, 5F-ADBICA; 
16  (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- 
17 3-carboxamide with substitution on the nitrogen atom of 
18 the indole ring by alkyl, haloalkyl, alkenyl, 
19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
20 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
21 2-(4-morpholinyl)ethyl, whether or not further substituted 
22 on the indole ring to any extent: including, but not 
23 limited to, ABICA, 5F-ABICA; 
24  (70) Methyl 2-(1H-indazole-3-carboxamido)-3- 
25 methylbutanoate with substitution on the nitrogen atom of 
26 the indazole ring by alkyl, haloalkyl, alkenyl, 
 
 
HB4352- 42 -LRB103 35349 RLC 65413 b


1 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
2 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
3 2-(4-morpholinyl)ethyl, whether or not further substituted 
4 on the indazole ring to any extent: including, but not 
5 limited to, AMB, 5F-AMB; 
6  (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- 
7 dimethylbutanoate with substitution on the nitrogen atom 
8 of the indazole ring by alkyl, haloalkyl, alkenyl, 
9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
10 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
11 2-(4-morpholinyl)ethyl, whether or not further substituted 
12 on the indazole ring to any extent: including, but not 
13 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; 
14  (72) Methyl 2-(1H-indole-3-carboxamido)-3- 
15 methylbutanoate with substitution on the nitrogen atom of 
16 the indole ring by alkyl, haloalkyl, alkenyl, 
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
19 2-(4-morpholinyl)ethyl, whether or not further substituted 
20 on the indazole ring to any extent: including, but not 
21 limited to, MMB018, MMB2201, and AMB-CHMICA; 
22  (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- 
23 dimethylbutanoate with substitution on the nitrogen atom 
24 of the indole ring by alkyl, haloalkyl, alkenyl, 
25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
26 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
 
 
HB4352- 43 -LRB103 35349 RLC 65413 b


1 2-(4-morpholinyl)ethyl, whether or not further substituted 
2 on the indazole ring to any extent: including, but not 
3 limited to, MDMB-CHMICA; 
4  (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- 
5 indazole-3-carboxamide with substitution on the nitrogen 
6 atom of the indazole ring by alkyl, haloalkyl, alkenyl, 
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
8 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
9 2-(4-morpholinyl)ethyl, whether or not further substituted 
10 on the indazole ring to any  extent: including, but not 
11 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA; 
12  (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- 
13 3-carboxamide with substitution on the nitrogen atom of 
14 the indole ring by alkyl, haloalkyl, alkenyl, 
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl 
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or 
17 2-(4-morpholinyl)ethyl, whether or not further substituted 
18 on the indazole ring to any extent: including, but not 
19 limited to, APP-PICA and 5-fluoro-APP-PICA; 
20  (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name 
21 4-AcO-DMT;
22  (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade 
23 name 5-MeO-MIPT;
24  (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
25  (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
26  (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
 
 
HB4352- 44 -LRB103 35349 RLC 65413 b


1  (81) 4-hydroxy-N-methyl-N-isopropyltryptamine 
2 (4-HO-MiPT); 
3  (82) Fluorophenylpiperazine;
4  (83) Methoxetamine;
5  (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- 
6 ethcathinone). 
7 (e) Unless specifically excepted or unless listed in 
8another schedule, any material, compound, mixture, or 
9preparation which contains any quantity of the following 
10substances having a depressant effect on the central nervous 
11system, including its salts, isomers, and salts of isomers 
12whenever the existence of such salts, isomers, and salts of 
13isomers is possible within the specific chemical designation:
14  (1) mecloqualone;
15  (2) methaqualone; and
16  (3) gamma hydroxybutyric acid.
17 (f) Unless specifically excepted or unless listed in 
18another schedule, any material, compound, mixture, or 
19preparation which contains any quantity of the following 
20substances having a stimulant effect on the central nervous 
21system, including its salts, isomers, and salts of isomers:
22  (1) Fenethylline;
23  (2) N-ethylamphetamine;
24  (3) Aminorex (some other names:

25 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

26 4-5-dihydro-5-phenyl-2-oxazolamine) and its

 
 
HB4352- 45 -LRB103 35349 RLC 65413 b


1 salts, optical isomers, and salts of optical isomers;
2  (4) Methcathinone (some other names:

3 2-methylamino-1-phenylpropan-1-one;

4 Ephedrone; 2-(methylamino)-propiophenone;

5 alpha-(methylamino)propiophenone; N-methylcathinone;

6 methycathinone; Monomethylpropion; UR 1431) and its

7 salts, optical isomers, and salts of optical isomers;
8  (5) Cathinone (some trade or other names:

9 2-aminopropiophenone; alpha-aminopropiophenone;

10 2-amino-1-phenyl-propanone; norephedrone);
11  (6) N,N-dimethylamphetamine (also known as:

12 N,N-alpha-trimethyl-benzeneethanamine;

13 N,N-alpha-trimethylphenethylamine);
14  (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

15 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
16  (8) 3,4-Methylenedioxypyrovalerone (MDPV); 
17  (9) Halogenated amphetamines and

18 methamphetamines - any compound derived from either

19 amphetamine or methamphetamine through the substitution

20 of a halogen on the phenyl ring, including, but not

21 limited to, 2-fluoroamphetamine, 3-

22 fluoroamphetamine and 4-fluoroamphetamine; 
23  (10) Aminopropylbenzofuran (APB):

24 including 4-(2-Aminopropyl) benzofuran, 5-

25 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)

26 benzofuran, and 7-(2-Aminopropyl) benzofuran; 
 
 
HB4352- 46 -LRB103 35349 RLC 65413 b


1  (11) Aminopropyldihydrobenzofuran (APDB):

2 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,

3 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,

4 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,

5 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
6  (12) Methylaminopropylbenzofuran

7 (MAPB): including 4-(2-methylaminopropyl)

8 benzofuran, 5-(2-methylaminopropyl)benzofuran,

9 6-(2-methylaminopropyl)benzofuran

10 and 7-(2-methylaminopropyl)benzofuran. 
11 (g) Temporary listing of substances subject to emergency 
12scheduling. Any material, compound, mixture, or preparation 
13that contains any quantity of the following substances:
14  (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide 
15 (benzylfentanyl), its optical isomers, isomers, salts, and 
16 salts of isomers;
17  (2) N-[1(2-thienyl) methyl-4-piperidyl]-N- 
18 phenylpropanamide (thenylfentanyl), its optical isomers, 
19 salts, and salts of isomers.
20 (h) Synthetic cathinones. Unless specifically excepted, 
21any chemical compound which is not approved by the United 
22States Food and Drug Administration or, if approved, is not 
23dispensed or possessed in accordance with State or federal 
24law, not including bupropion, structurally derived from 
252-aminopropan-1-one by substitution at the 1-position with 
26either phenyl, naphthyl, or thiophene ring systems, whether or 
 
 
HB4352- 47 -LRB103 35349 RLC 65413 b


1not the compound is further modified in one or more of the 
2following ways: 
3  (1) by substitution in the ring system to any extent 
4 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or 
5 halide substituents, whether or not further substituted in 
6 the ring system by one or more other univalent 
7 substituents. Examples of this class include, but are not 
8 limited to, 3,4-Methylenedioxycathinone (bk-MDA); 
9  (2) by substitution at the 3-position with an acyclic 
10 alkyl substituent. Examples of this class include, but are 
11 not limited to, 2-methylamino-1-phenylbutan-1-one 
12 (buphedrone); or 
13  (3) by substitution at the 2-amino nitrogen atom with 
14 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by 
15 inclusion of the 2-amino nitrogen atom in a cyclic 
16 structure. Examples of this class include, but are not 
17 limited to, Dimethylcathinone, Ethcathinone, and 
18 a-Pyrrolidinopropiophenone (a-PPP); or 
19 Any other synthetic cathinone which is not approved by the 
20United States Food and Drug Administration or, if approved, is 
21not dispensed or possessed in accordance with State or federal 
22law. 
23 (i) Synthetic cannabinoids or piperazines. Any synthetic 
24cannabinoid or piperazine which is not approved by the United 
25States Food and Drug Administration or, if approved, which is 
26not dispensed or possessed in accordance with State and 
 
 
HB4352- 48 -LRB103 35349 RLC 65413 b


1federal law.
2 (j) Unless specifically excepted or listed in another 
3schedule, any chemical compound which is not approved by the 
4United States Food and Drug Administration or, if approved, is 
5not dispensed or possessed in accordance with State or federal 
6law, and is derived from the following structural classes and 
7their salts:
8  (1) Benzodiazepine class: A fused 1,4-diazepine and 
9 benzene ring structure with a phenyl connected to the 
10 1,4-diazepine ring, with any substitution(s) or 
11 replacement(s) on the 1,4-diazepine or benzene ring, any 
12 substitution(s) on the phenyl ring, or any combination 
13 thereof. Examples of this class include but are not 
14 limited to: Clonazolam, Flualprazolam; or
15  (2) Thienodiazepine class: A fused 1,4-diazepine and 
16 thiophene ring structure with a phenyl connected to the 
17 1,4-diazepine ring, with any substitution(s) or 
18 replacement(s) on the 1,4-diazepine or thiophene ring, any 
19 substitution(s) on the phenyl ring, or any combination 
20 thereof. Examples of this class include but are not 
21 limited to: Etizolam. 
22(Source: P.A. 103-245, eff. 1-1-24.)

23 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
24 Sec. 206. (a) The controlled substances listed in this 
25Section are included in Schedule II.
 
 
HB4352- 49 -LRB103 35349 RLC 65413 b


1 (b) Unless specifically excepted or unless listed in 
2another schedule, any of the following substances whether 
3produced directly or indirectly by extraction from substances 
4of vegetable origin, or independently by means of chemical 
5synthesis, or by combination of extraction and chemical 
6synthesis:
7  (1) Opium and opiates, and any salt, compound, 
8 derivative or preparation of opium or opiate, excluding 
9 apomorphine, dextrorphan, levopropoxyphene, nalbuphine, 
10 nalmefene, naloxone, and naltrexone, and their respective 
11 salts, but including the following:
12   (i) Raw Opium;
13   (ii) Opium extracts;
14   (iii) Opium fluid extracts;
15   (iv) Powdered opium;
16   (v) Granulated opium;
17   (vi) Tincture of opium;
18   (vii) Codeine;
19   (viii) Ethylmorphine;
20   (ix) Etorphine Hydrochloride;
21   (x) Hydrocodone;
22   (xi) Hydromorphone;
23   (xii) Metopon;
24   (xiii) Morphine;
25   (xiii.5) 6-Monoacetylmorphine; 
26   (xiv) Oxycodone;
 
 
HB4352- 50 -LRB103 35349 RLC 65413 b


1   (xv) Oxymorphone;
2   (xv.5) Tapentadol; 
3   (xvi) Thebaine;
4   (xvii) Thebaine-derived butorphanol.
5   (xviii) Methorphan, except drug products 
6 containing dextromethorphan that may be dispensed 
7 pursuant to a prescription order of a practitioner and 
8 are sold in compliance with the safety and labeling 
9 standards as set forth by the United States Food and 
10 Drug Administration, or drug products containing 
11 dextromethorphan that are sold in solid, tablet, 
12 liquid, capsule, powder, thin film, or gel form and 
13 which are formulated, packaged, and sold in dosages 
14 and concentrations for use as an over-the-counter drug 
15 product. For the purposes of this Section, 
16 "over-the-counter drug product" means a drug that is 
17 available to consumers without a prescription and sold 
18 in compliance with the safety and labeling standards 
19 as set forth by the United States Food and Drug 
20 Administration. 
21  (2) Any salt, compound, isomer, derivative or 
22 preparation thereof which is chemically equivalent or 
23 identical with any of the substances referred to in 
24 subparagraph (1), but not including the isoquinoline 
25 alkaloids of opium;
26  (3) Opium poppy and poppy straw;
 
 
HB4352- 51 -LRB103 35349 RLC 65413 b


1  (4) Coca leaves and any salt, compound, isomer, salt 
2 of an isomer, derivative, or preparation of coca leaves 
3 including cocaine or ecgonine, and any salt, compound, 
4 isomer, derivative, or preparation thereof which is 
5 chemically equivalent or identical with any of these 
6 substances, but not including decocainized coca leaves or 
7 extractions of coca leaves which do not contain cocaine or 
8 ecgonine (for the purpose of this paragraph, the term 
9 "isomer" includes optical, positional and geometric 
10 isomers);
11  (5) Concentrate of poppy straw (the crude extract of 
12 poppy straw in either liquid, solid or powder form which 
13 contains the phenanthrine alkaloids of the opium poppy).
14 (c) Unless specifically excepted or unless listed in 
15another schedule any of the following opiates, including their 
16isomers, esters, ethers, salts, and salts of isomers, whenever 
17the existence of these isomers, esters, ethers and salts is 
18possible within the specific chemical designation, dextrorphan 
19excepted:
20  (1) Alfentanil;
21  (1.1) Carfentanil;
22  (1.2) Thiafentanyl; 
23  (2) Alphaprodine;
24  (3) Anileridine;
25  (4) Bezitramide;
26  (5) Bulk Dextropropoxyphene (non-dosage forms);
 
 
HB4352- 52 -LRB103 35349 RLC 65413 b


1  (6) Dihydrocodeine;
2  (7) Diphenoxylate;
3  (8) Fentanyl;
4  (9) Sufentanil;
5  (9.5) Remifentanil;
6  (10) Isomethadone;
7  (11) (Blank);
8  (12) Levorphanol (Levorphan);
9  (13) Metazocine;
10  (14) Methadone;
11  (15) Methadone-Intermediate,

12 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
13  (16) Moramide-Intermediate,

14 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic

15 acid;
16  (17) Pethidine (meperidine);
17  (18) Pethidine-Intermediate-A,

18 4-cyano-1-methyl-4-phenylpiperidine;
19  (19) Pethidine-Intermediate-B,

20 ethyl-4-phenylpiperidine-4-carboxylate;
21  (20) Pethidine-Intermediate-C,

22 1-methyl-4-phenylpiperidine-4-carboxylic acid;
23  (21) Phenazocine;
24  (22) Piminodine;
25  (23) Racemethorphan;
26  (24) (Blank);
 
 
HB4352- 53 -LRB103 35349 RLC 65413 b


1  (25) Levo-alphacetylmethadol (some other names: 
2 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
3 (d) Unless specifically excepted or unless listed in 
4another schedule, any material, compound, mixture, or 
5preparation which contains any quantity of the following 
6substances having a stimulant effect on the central nervous 
7system:
8  (1) Amphetamine, its salts, optical isomers, and salts 
9 of its optical isomers;
10  (2) Methamphetamine, its salts, isomers, and salts of 
11 its isomers;
12  (3) Phenmetrazine and its salts;
13  (4) Methylphenidate;
14  (5) Lisdexamfetamine. 
15 (e) Unless specifically excepted or unless listed in 
16another schedule, any material, compound, mixture, or 
17preparation which contains any quantity of the following 
18substances having a depressant effect on the central nervous 
19system, including its salts, isomers, and salts of isomers 
20whenever the existence of such salts, isomers, and salts of 
21isomers is possible within the specific chemical designation:
22  (1) Amobarbital;
23  (2) Secobarbital;
24  (3) Pentobarbital;
25  (4) Pentazocine;
26  (5) Phencyclidine;
 
 
HB4352- 54 -LRB103 35349 RLC 65413 b


1  (6) Gluthethimide;
2  (7) (Blank). 
3 (f) Unless specifically excepted or unless listed in 
4another schedule, any material, compound, mixture, or 
5preparation which contains any quantity of the following 
6substances:
7  (1) Immediate precursor to amphetamine and 
8 methamphetamine:
9   (i) Phenylacetone
10  Some trade or other names: phenyl-2-propanone;
11  P2P; benzyl methyl ketone; methyl benzyl ketone.
12  (2) Immediate precursors to phencyclidine:
13   (i) 1-phenylcyclohexylamine;
14   (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
15  (3) Nabilone.
16  (4) Xylazine: N-(2,6-dimethylpheny1)-5,6-dihydro- 
17 4H-1,3-thiazin-2-amine), including its isomers, esters, 
18 ethers, salts, and salts of isomers, esters, and ethers, 
19 whenever the existence of such isomers, esters, ethers, 
20 and salts is possible within the specific chemical 
21 designation as a Schedule II controlled substance.
22 (g) Clonazolam. 
23(Source: P.A. 100-368, eff. 1-1-18.)

24 Section 95. No acceleration or delay. Where this Act makes 
25changes in a statute that is represented in this Act by text 
 
 
HB4352- 55 -LRB103 35349 RLC 65413 b